Antibodies News and Research

RSS

The impact of multiple sclerosis therapy on COVID-19 vaccine efficacy

In a paper, the vaccine-induced cellular and immune response of MS patients receiving a range of therapies are assessed.

23 Sep 2021

Antibody kinetics in recovered COVID-19 patients

Researchers from Tel Aviv University have been examining the kinetics of antibodies in recovered COVID-19 patients.

23 Sep 2021

Biosimilar drugs are cheaper than biologics. Are they similar enough to switch?

It took years for Elle Moxley to get a diagnosis that explained her crippling gastrointestinal pain, digestion problems, fatigue, and hot, red rashes.

23 Sep 2021

McLean wins NIH grant to explore links between COVID-19 vaccine and menstrual cycle changes

In research that will add important data to the experience of vaccines on women's health, Laura Payne, PhD, director of McLean Hospital's Clinical and Translational Pain Research Laboratory, has received a grant from the National Institutes of Health to explore potential links between SARS-CoV-2 vaccination and menstrual cycle changes.

23 Sep 2021

Researchers encourage longer dosing intervals for Pfizer-BioNTech’s COVID-19 vaccine

Researchers in Canada, Italy, and the United States have encouraged extending the interval time between two doses of Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine among individuals who have not previously been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

22 Sep 2021

Pregnant women who receive COVID-19 vaccine pass high levels of antibodies to their babies

Women who receive the mRNA COVID-19 vaccine during pregnancy pass high levels of antibodies to their babies, a new study finds.

22 Sep 2021

mRNA-based and adenoviral vector-based COVID-19 vaccines elicit diverse humoral immunity

Scientists from the USA have recently compared the dynamics of humoral and cellular immune responses induced by mRNA-based and adenoviral vector-based coronavirus disease 2019 (COVID-19) vaccines. The findings reveal a difference in humoral immune responses. The study is currently available on the medRxiv* preprint server.

22 Sep 2021

The role of nanomaterials during the COVID-19 pandemic

A new review published in Rare Metals has focused on the applications of nanomaterials to fight the ongoing COVID-19 pandemic.

22 Sep 2021

Unique tiny Ilamas antibodies could be used for treatment of COVID-19

A unique type of tiny antibody produced by llamas could provide a new frontline treatment against Covid-19 that can be taken by patients as a simple nasal spray.

22 Sep 2021

PerkinElmer Completes Acquisition of Antibody and Reagent Leader BioLegend

PerkinElmer today announced it has completed its acquisition of BioLegend, a leading, worldwide provider of life science antibodies and reagents.

From Revvity 22 Sep 2021

Those undergoing treatment for hematological malignancies show reduced immune response to COVID-19 vaccines

Researchers recently investigated the effect of infection with SARS-CoV-2 in patients with hematologic malignancies in minority populations.

21 Sep 2021

Implications of dosing sparing and booster shots in the context of prior SARS-CoV-2 infection

The current study suggests that deferring the second vaccination of individuals with prior infection may be a cost-effective strategy.

21 Sep 2021

Comparison of recombinant SARS-CoV-2 receptor binding domain produced in mammalian, insect, and bacterial cells

In a recent study, RBD produced in various cell types are characterized in-depth, comparing their applicability for future COVID-19 research.

21 Sep 2021

COVID-19 induces the generation of distinct autoantibodies

In a recent study, the association between COVID-19 and autoimmunity is investigated at all levels of disease severity.

21 Sep 2021

Researchers provide structural insights into HCV receptor binding and entry

In a new paper published in Nature, scientists from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, describe the structure of a key protein on the surface of the hepatitis C virus (HCV) and how it interacts with its receptor found on some human cells.

21 Sep 2021

Antibodies News and Research

The impact of multiple sclerosis therapy on COVID-19 vaccine efficacy

Antibody kinetics in recovered COVID-19 patients

Biosimilar drugs are cheaper than biologics. Are they similar enough to switch?

McLean wins NIH grant to explore links between COVID-19 vaccine and menstrual cycle changes

Researchers encourage longer dosing intervals for Pfizer-BioNTech’s COVID-19 vaccine

Pregnant women who receive COVID-19 vaccine pass high levels of antibodies to their babies

mRNA-based and adenoviral vector-based COVID-19 vaccines elicit diverse humoral immunity

The role of nanomaterials during the COVID-19 pandemic

Unique tiny Ilamas antibodies could be used for treatment of COVID-19

PerkinElmer Completes Acquisition of Antibody and Reagent Leader BioLegend

Those undergoing treatment for hematological malignancies show reduced immune response to COVID-19 vaccines

Implications of dosing sparing and booster shots in the context of prior SARS-CoV-2 infection

Comparison of recombinant SARS-CoV-2 receptor binding domain produced in mammalian, insect, and bacterial cells

COVID-19 induces the generation of distinct autoantibodies

Researchers provide structural insights into HCV receptor binding and entry

Three US COVID-19 vaccines provide substantial protection against hospitalization

New cell-free antibody generation platform successfully creates neutralizing antibodies effective against SARS-CoV-2

Decline in SARS-CoV-2 neutralizing antibodies and unique cytokine profile in severe COVID-19 patients

Careful pipetting reduces the stress on cells in culture

Maintenance dialysis patients may need additional shots of COVID-19 vaccines

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo